{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ustekinumab", "query": { "intervention": "Ustekinumab" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 101, "total_pages": 11, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ustekinumab&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-04T02:48:37.807Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01708603", "title": "P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Moderate to Severe Plaque Psoriasis" ], "interventions": [ { "name": "210 mg brodalumab", "type": "DRUG" }, { "name": "140 mg brodalumab", "type": "DRUG" }, { "name": "ustekinumab", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bausch Health Americas, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 1831, "start_date": "2012-08", "completion_date": "2015-10", "has_results": true, "last_update_posted_date": "2020-01-06", "last_synced_at": "2026-09-04T02:48:37.807Z", "location_count": 67, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 56 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01708603" }, { "nct_id": "NCT03881059", "title": "Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Active Psoriatic Arthritis" ], "interventions": [ { "name": "BMS-986165 Placebo", "type": "OTHER" }, { "name": "BMS-986165 Dose A", "type": "DRUG" }, { "name": "BMS-986165 Dose B", "type": "DRUG" }, { "name": "Ustekinumab", "type": "DRUG" }, { "name": "Ustekinumab Placebo", "type": "OTHER" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 203, "start_date": "2019-04-01", "completion_date": "2021-01-27", "has_results": true, "last_update_posted_date": "2022-02-15", "last_synced_at": "2026-09-04T02:48:37.807Z", "location_count": 31, "location_summary": "Huntsville, Alabama • Covina, California • La Jolla, California + 27 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Covina", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Aventura", "state": "Florida" }, { "city": "Miami Lakes", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03881059" }, { "nct_id": "NCT03266471", "title": "Cytokines and Genes in Therapeutic Response in Crohn's Disease", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Inflammatory Bowel Diseases" ], "interventions": [ { "name": "Baseline blood sample", "type": "DIAGNOSTIC_TEST" }, { "name": "Baseline intestinal biopsies", "type": "DIAGNOSTIC_TEST" }, { "name": "Crohn's disease activity index (CDAI)", "type": "OTHER" }, { "name": "Post treatment blood sample", "type": "DIAGNOSTIC_TEST" }, { "name": "Post treatment intestinal biopsies", "type": "DIAGNOSTIC_TEST" }, { "name": "Baseline stool sample", "type": "DIAGNOSTIC_TEST" }, { "name": "Post treatment stool sample", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST", "OTHER" ], "sponsor": "Vanderbilt University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 96, "start_date": "2017-10-13", "completion_date": "2022-05-03", "has_results": false, "last_update_posted_date": "2023-04-14", "last_synced_at": "2026-09-04T02:48:37.807Z", "location_count": 2, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03266471" }, { "nct_id": "NCT04852666", "title": "Comparative Effectiveness of Biologics or Small Molecule Therapies in Inflammatory Bowel Disease (IBD)", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Crohn's Disease", "Ulcerative Colitis" ], "interventions": [], "intervention_types": [], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 465, "start_date": "2019-07-25", "completion_date": "2022-12-15", "has_results": true, "last_update_posted_date": "2024-06-14", "last_synced_at": "2026-09-04T02:48:37.807Z", "location_count": 2, "location_summary": "New York, New York • Chapel Hill, North Carolina", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04852666" }, { "nct_id": "NCT02054481", "title": "BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "BI 655066", "type": "DRUG" }, { "name": "Ustekinumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 166, "start_date": "2014-02", "completion_date": "2015-07", "has_results": true, "last_update_posted_date": "2016-09-19", "last_synced_at": "2026-09-04T02:48:37.807Z", "location_count": 12, "location_summary": "Los Angeles, California • Port Orange, Florida • Arlington Hts, Illinois + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Port Orange", "state": "Florida" }, { "city": "Arlington Hts", "state": "Illinois" }, { "city": "Bay City", "state": "Michigan" }, { "city": "Fridley", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02054481" }, { "nct_id": "NCT07116967", "title": "Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Plaque Psoriasis" ], "interventions": [ { "name": "Deucravacitinib", "type": "DRUG" }, { "name": "Ustekinumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 3040, "start_date": "2025-09-22", "completion_date": "2031-01-16", "has_results": false, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-09-04T02:48:37.807Z", "location_count": 122, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 101 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT07116967" }, { "nct_id": "NCT03782376", "title": "A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Crohn Disease" ], "interventions": [ { "name": "Ustekinumab approximately 6 mg/kg (IV)", "type": "DRUG" }, { "name": "Placebo (SC)", "type": "DRUG" }, { "name": "Placebo (IV)", "type": "DRUG" }, { "name": "Ustekinumab 90 mg (SC) Group 1", "type": "DRUG" }, { "name": "Ustekinumab 90 mg (SC) Group 2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen-Cilag Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 215, "start_date": "2018-12-20", "completion_date": "2023-01-10", "has_results": true, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-09-04T02:48:37.807Z", "location_count": 28, "location_summary": "La Jolla, California • Colorado Springs, Colorado • Gainesville, Florida + 22 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03782376" }, { "nct_id": "NCT00307437", "title": "A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg", "type": "DRUG" }, { "name": "Ustekinumab (CNTO 1275) 45 mg", "type": "DRUG" }, { "name": "Ustekinumab (CNTO 1275) 90 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Centocor Research & Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1230, "start_date": "2005-05", "completion_date": "2011-10", "has_results": true, "last_update_posted_date": "2013-01-24", "last_synced_at": "2026-09-04T02:48:37.807Z", "location_count": 28, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00307437" }, { "nct_id": "NCT07352566", "title": "Utilization of a Microdevice for Psoriasis and Atopic Dermatitis", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Psoriasis", "Atopic Dermatitis" ], "interventions": [ { "name": "In situ cutaneous microdevice", "type": "DEVICE" }, { "name": "Triamcinolone", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Calcipotriene", "type": "DRUG" }, { "name": "Tapinarof", "type": "DRUG" }, { "name": "Crisaborole", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Etanercept", "type": "DRUG" }, { "name": "Certolizumab", "type": "DRUG" }, { "name": "Infliximab", "type": "DRUG" }, { "name": "Secukinumab", "type": "DRUG" }, { "name": "Ixekizumab", "type": "DRUG" }, { "name": "Apremilast", "type": "DRUG" }, { "name": "Risankizumab", "type": "DRUG" }, { "name": "Ustekinumab", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Mycophenolate", "type": "DRUG" }, { "name": "Azathioprine", "type": "DRUG" }, { "name": "Chloroquine", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Tofacitinib", "type": "DRUG" }, { "name": "Deucravacitinib", "type": "DRUG" }, { "name": "Dupilumab", "type": "DRUG" }, { "name": "Tralokinumab", "type": "DRUG" }, { "name": "Guselkumab", "type": "DRUG" }, { "name": "Tildrakizumab", "type": "DRUG" }, { "name": "Baractinib", "type": "DRUG" }, { "name": "Abrocitinib", "type": "DRUG" }, { "name": "Upadacitinib", "type": "DRUG" }, { "name": "Lebrikizumab", "type": "DRUG" }, { "name": "Nemolizumab", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Bimekizumab", "type": "DRUG" }, { "name": "Roflumilast", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2026-08-01", "completion_date": "2030-06-01", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-09-04T02:48:37.807Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07352566" }, { "nct_id": "NCT06274554", "title": "Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Crohn's Disease", "Inflammatory Bowel Diseases" ], "interventions": [ { "name": "Fluconazole", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "IL-23 Therapy", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2024-10-04", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-09-04T02:48:37.807Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06274554" } ] }